Certolizumab pegol (Cimzia®) gained FDA approval in September/October 2013 for two new indications, adults with active psoriatic arthritis (PsA) and adults with active ankylosing spondylitis (AS).
Certolizumab pegol gains FDA approval for PsA and AS
Ankylosing Spondylitis News
Challenges in Screening for Latent TB in Inflammatory Arthritis
Screening for latent TB in patients with inflammatory arthritis who will be starting TNFα inhibitors is important to prevent complications of TB-reactivation. However, currently there is no ‘gold standard’ for the diagnosis of latent TB.
Arthritis News: Golimumab Receives FDA Approval
[…]
Is TNF Inhibitor Therapy Effective at Preventing Bony Ankylosis in Ankylosing Spondylitis?
[…]
Efficacy and Safety of Adalimumab in Patients with Active Ankylosing Spondylitis
Tumor necrosis factor alpha (TNF-a) is a highly inflammatory cytokine with an important role in coordinating the inflammatory response seen in the axial skeleton of patients with ankylosing spondylitis (AS). Two biologic inhibitors of this cytokine, etanercept (Enbrel) and infliximab (Remicade), have been shown to be effective at reducing the subjective symptoms and reducing the systemic inflammatory response in AS in randomized clinical trials.
Infliximab (Remicade) Approved in Europe for Treatment of Ankylosing Spondylitis
Infliximab (Remicade®) is now approved in Europe for the treatment of ankylosing spondylitis (AS) patients who have severe axial symptoms, elevated serological markers of inflammatory activity and who have had an inadequate response to conventional therapy.
